Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allergan plc stock logo
AGN
Allergan
$193.02
$190.89
$114.27
$202.21
$63.50B1.24.01 million shs12.44 million shs
The Gap, Inc. stock logo
GPS
GAP
$23.22
$9.38
$30.75
$9.21B2.387.63 million shs7.17 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$799.32
-2.7%
$829.78
$711.40
$972.53
$759.60B0.343.12 million shs2.58 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.61
-0.4%
$26.28
$24.48
$31.54
$145.34B0.6139.84 million shs26.94 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$10.70
-3.9%
$6.57
$0.13
$1.04
$206.06M1.581.05 million shs7.30 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allergan plc stock logo
AGN
Allergan
0.00%0.00%0.00%0.00%0.00%
The Gap, Inc. stock logo
GPS
GAP
0.00%0.00%0.00%0.00%+8.05%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.21%-11.60%-5.33%+5.10%+8.92%
Pfizer Inc. stock logo
PFE
Pfizer
-1.05%-0.78%-0.54%+1.40%-8.16%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+31.87%+168.19%+3.63%+361.83%+3,444.59%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allergan plc stock logo
AGN
Allergan
N/AN/AN/AN/AN/AN/AN/AN/A
The Gap, Inc. stock logo
GPS
GAP
3.1371 of 5 stars
3.30.02.51.00.02.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.7781 of 5 stars
3.43.03.34.02.81.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9761 of 5 stars
3.33.04.24.22.83.33.1
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.3836 of 5 stars
1.30.00.00.01.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allergan plc stock logo
AGN
Allergan
0.00
N/AN/AN/A
The Gap, Inc. stock logo
GPS
GAP
2.53
Moderate Buy$27.08∞ Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7226.32% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.59
Moderate Buy$31.9224.68% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.50
Moderate Buy$3.00-71.96% Downside

Current Analyst Ratings Breakdown

Latest VIRI, AGN, LLY, PFE, and GPS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,000.00 ➝ $970.00
1/28/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $29.00
1/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$950.00
1/16/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$970.00
(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allergan plc stock logo
AGN
Allergan
$16.09B3.95$36.70 per share5.26$177.28 per share1.09
The Gap, Inc. stock logo
GPS
GAP
$15.00B0.00N/A8.11$7.00 per share0.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.83$13.03 per share61.34$15.05 per share53.11
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.28$4.01 per share6.38$15.81 per share1.62
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allergan plc stock logo
AGN
Allergan
-$5.27B$17.64N/A10.651.63-15.44%8.46%5.31%N/A
The Gap, Inc. stock logo
GPS
GAP
$502M$1.8013.640.001.404.52%27.57%6.30%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7168.4125.681.4023.51%85.24%16.19%4/29/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4118.198.450.6412.62%19.47%8.09%4/29/2025 (Estimated)
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%5/7/2025 (Estimated)

Latest VIRI, AGN, LLY, PFE, and GPS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allergan plc stock logo
AGN
Allergan
$2.961.53%N/A16.78%N/A
The Gap, Inc. stock logo
GPS
GAP
$0.602.55%+35.25%33.33%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.75%+15.21%51.24%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.72%+2.50%121.99%16 Years
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allergan plc stock logo
AGN
Allergan
0.31
1.01
0.84
The Gap, Inc. stock logo
GPS
GAP
0.55
1.50
0.80
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Allergan plc stock logo
AGN
Allergan
83.91%
The Gap, Inc. stock logo
GPS
GAP
58.81%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
Allergan plc stock logo
AGN
Allergan
0.08%
The Gap, Inc. stock logo
GPS
GAP
30.81%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allergan plc stock logo
AGN
Allergan
17,400329.00 millionN/AOptionable
The Gap, Inc. stock logo
GPS
GAP
85,000375.07 million259.51 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable

Recent News About These Companies

Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allergan stock logo

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

GAP stock logo

GAP NYSE:GPS

The Gap, Inc. operates as an apparel retail company. The company offers apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands. Its products include adult apparel and accessories; and fitness and lifestyle products for use in yoga, training, sports, travel, and everyday activities for women and girls. The company offers its products through company-operated stores, franchise stores, websites, and third-party arrangements. It has franchise agreements to operate Old Navy, Gap, Banana Republic, and Athleta stores and websites in Asia, Europe, Latin America, the Middle East, and Africa. The Gap, Inc. was incorporated in 1969 and is headquartered in San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$799.32 -22.55 (-2.74%)
As of 03:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$25.60 -0.11 (-0.41%)
As of 03:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$10.70 -0.43 (-3.86%)
As of 03/12/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.